ライフサイエンスコーパス: varicella vaccine

1 ides induced in vivo after immunization with varicella vaccine.

2 ted rash after receiving the live attenuated varicella vaccine.

3 who received 2 doses compared with 1 dose of varicella vaccine.

4 rates, before and after 1 dose of Merck/Oka varicella vaccine.

5 rarely have disease triggered by receipt of varicella vaccine.

6 ed 60-75 years (a comparison group) received varicella vaccine.

7 genic potential of individual strains in the varicella vaccine.

8 microL are likely to benefit from receiving varicella vaccine.

9 increased concern about the effectiveness of varicella vaccine.

10 n immunocompromised patient who received the varicella vaccine.

11 respiratory distress 5 weeks after receiving varicella vaccine.

12 administered measles, mumps, and rubella and varicella vaccines.

13 se of the currently marketed live attenuated varicella vaccine (3625 pfu) or of a partially heat-inac

14 22 controls (15.7%) had received 2 doses of varicella vaccine, 66 cases (93.0%) vs 117 controls (83.

15 n investigational Oka strain live attenuated varicella vaccine, a 38-year-old healthy white woman dev

16 e reports of adverse events in recipients of varicella vaccine, a rate of 67.5 reports per 100,000 do

17 Varicella vaccine administered under routine conditions

18 Thus, varicella vaccine, administered carefully with close fol

19 Clinical trials of varicella vaccine administration to immunocompromised ch

20 Efficacy of one-dose varicella vaccine against all varicella was 65.4% (57.2-

21 and rubella and measles, mumps, rubella, and varicella vaccines among children who are 1 year of age.

22 its licensure in 1995, the extensive use of varicella vaccine and close surveillance of the associat

23 The immunogenicity of heat-inactivated varicella vaccine and effects on VZV pathogenesis were e

24 f varicella vaccine who had 1 or > 1 dose of varicella vaccine and in those who did or did not have a

25 valent combined measles, mumps, rubella, and varicella vaccine and measles-mumps-rubella and varicell

26 V) was developed to increase the coverage of varicella vaccine and reduce the number of injections ch

27 cinated population after the introduction of varicella vaccine and to determine the number of prevent

28 ic assays and to eliminate confusion between varicella vaccine and varicella zoster immunoglobulin.

29 recommended adding a routine second dose of varicella vaccine and weighed economic projections as we

30 been reported since the introduction of the varicella vaccine, and a booster vaccination may be nece

31 Humoral immune responses to varicella vaccine are best achieved when children with P

32 the reported adverse events associated with varicella vaccine are minor, and serious risks appear to

33 data on a group of individuals who received varicella vaccine as healthy young adults 10-26 years ag

34 the strain carried 15 of 42 (36%) recognized varicella vaccine-associated single-nucleotide polymorph

35 roup), or (2) MMR at dose one and monovalent varicella vaccine at dose two (MMR+V group), or (3) two

36 icella vaccine and measles-mumps-rubella and varicella vaccines at separate injection sites given at

37 ts show that the clinical attenuation of the varicella vaccine can be attributed to decreased replica

38 n children with leukemia in remission by the Varicella Vaccine Collaborative Study.

39 In seven studies of the effectiveness of the varicella vaccine conducted since it was licensed, the e

40 Despite 29 breakthrough cases, the varicella vaccine conferred a high degree of protection

41 as associated with a 4.0% increase in 1-dose varicella vaccine coverage.

42 Varicella vaccine currently is recommended for children

43 A live attenuated varicella vaccine, derived from the Oka strain of VZV ha

44 A previously healthy boy who had received varicella vaccine developed herpes zoster with meningiti

45 ed complications demonstrates that 1 dose of varicella vaccine does not prevent serious disease in al

46 ecommended that children routinely receive 2 varicella vaccine doses in place of the 1 dose previousl

47 ) recommended administering a second dose of varicella vaccine during outbreaks, supplementing the ro

48 Varicella vaccine effectiveness against all forms of dis

49 Varicella vaccine effectiveness was calculated among chi

50 aricella syndrome or other birth defects and varicella vaccine exposure during pregnancy.

51 accine uptake for 2-dose MCV and single-dose varicella vaccine, focusing on timeliness.

52 vaccine policy recommendation of 2 doses of varicella vaccine for all school-aged children should be

53 After US licensure of the Merck varicella vaccine for immunocompetent persons on 17 Marc

54 Inactivated varicella vaccine given before hematopoietic-cell transp

55 a undeniably indicate that immunization with varicella vaccine has been and continues to be successfu

56 arding the impact that the widespread use of varicella vaccine has had on the epidemiology of varicel

57 n in the United States who have received the varicella vaccine has increased there have been several

58 Although 1 dose of varicella vaccine has provided excellent protection, a h

59 One dose of varicella vaccine, however, elicits detectable immune re

60 Before licensure of varicella vaccine in 1995, varicella was a universal chi

61 We assessed the effectiveness of 2 doses of varicella vaccine in a case-control study by identifying

62 This experience with varicella vaccine in BMT patients is the first evidence

63 rubella vaccine administered with or without varicella vaccine in both younger and older children.

64 On the basis of studies of the varicella vaccine in healthy and immunosuppressed childr

65 Varicella vaccine in immunocompromised children was clin

66 ertaken to develop guidelines for the use of varicella vaccine in immunocompromised children.

67 The effectiveness of 2 doses of varicella vaccine in the first 2.5 years after recommend

68 Widespread use of varicella vaccine in the United States could enable dete

69 Widespread use of the varicella vaccine in the United States has led to import

70 virus (VZV)-containing vaccine (hereafter, "varicella vaccine") in frail nursing homes residents nor

71 Similarly, VZV-RCF after varicella vaccine increased with age in subjects aged <1

72 The Oka/Merck varicella vaccine induces VZV immunity in elderly nursin

73 mended 2-dose childhood vaccine schedule for varicella vaccine is a priority.

74 The combination measles, mumps, rubella, and varicella vaccine is associated with a 2-fold increased

75 Although varicella vaccine is effective, its effectiveness decrea

76 A second dose of varicella vaccine is expected to increase seroconversion

77 Although varicella vaccine is given to clinically stable human im

78 The current varicella vaccine is highly attenuated in the skin and y

79 Varicella vaccine is highly effective as used in clinica

80 Live attenuated varicella vaccine is recommended for healthy individuals

81 The licensed, live attenuated varicella vaccine is safe and immunogenic in HIV-infecte

82 icted that immunization with live attenuated varicella vaccine is unlikely to be deleterious to HIV-i

83 live [Oka/Merck]; Merck), a live attenuated varicella vaccine, is indicated for vaccination against

84 e varicella incidence has declined following varicella vaccine licensure, herpes zoster (HZ) cases ma

85 1 in every 5 children who receives 1 dose of varicella vaccine may develop varicella disease, also kn

86 The varicella vaccine may eventually reduce or eliminate her

87 vaccine or a combined measles-mumps-rubella-varicella vaccine (MMRV).

88 Because lyophilized varicella vaccine must be stored frozen at -15 degrees C

89 A second dose of varicella vaccine, now recommended for all children, cou

90 uated after 1 and 2 doses of live attenuated varicella vaccine, Oka strain, in several studies.

91 Immunisation is possible with monovalent varicella vaccine or a combined measles-mumps-rubella-va

92 n-Hodgkin's or Hodgkin's lymphoma to receive varicella vaccine or no vaccine.

93 a in naive children administered one dose of varicella vaccine or two doses of MMRV.

94 use of the combination measles-mumps-rubella-varicella vaccine over separate measles-mumps-rubella an

95 s (7.0%) vs 1 control (0.7%) did not receive varicella vaccine (P < .001).

96 ill require further study to clarify whether varicella vaccine plays a role.

97 Varicella vaccine preferably should be given to children

98 Introduction of a universal varicella vaccine program for U.S. children in 1996 spar

99 A second dose of varicella vaccine raises response rates to 99% and was r

100 were stratified by age: less than 20 years (varicella vaccine recommended), 20 to 59 years (no vacci

101 Although the role of varicella vaccine remained unproven in most serious adve

102 n the United States, studies have shown that varicella vaccine's overall effectiveness ranges from 44

103 e prompted the recommendation for a two-dose varicella vaccine series.

104 ation Practices for a routine second dose of varicella vaccine should lead to better varicella diseas

105 ldren with asthma, in those who received the varicella vaccine soon after the measles, mumps, and rub

106 The live, attenuated varicella vaccine strain (vOka) is the only licensed the

107 Pregnant women occasionally received varicella vaccine through confusion with varicella zoste

108 Many studies have shown varicella vaccine to be highly effective.

109 Administration of varicella vaccine to HIV-infected or uninfected individu

110 Since the introduction of the varicella vaccine to the routine immunization schedule,

111 This case documents transmission of varicella vaccine type virus from a healthy vaccinee to

112 Despite no change in the scheduled age of varicella vaccine, use of MMRV vaccine was associated wi

113 Varicella vaccine (Varivax, Merck) has been available in

114 ing on polymorphisms between live attenuated varicella vaccine virus and wild-type varicella-zoster v

115 The live attenuated varicella vaccine virus exhibited the same pattern of sh

116 A live, attenuated varicella vaccine (vOka) was generated by using the VZV

117 The live attenuated Oka varicella vaccine (vOka), derived from clade 2 wild-type

118 One dose of varicella vaccine was 84.5% effective (median; range, 44

119 ing outbreaks of varicella, a second dose of varicella vaccine was added to the routine immunization

120 A live attenuated varicella vaccine was approved for use in the United Sta

121 f vaccine type, measles, mumps, rubella, and varicella vaccine was associated with a 1.4-fold increas

122 ensure of the combined measles-mumps-rubella-varicella vaccine was completed, which allowed harmoniza

123 A live attenuated varicella vaccine was developed in 1974 and was approved

124 Heat-inactivated, live attenuated varicella vaccine was given within 30 days before transp

125 Under conditions of intense exposure, varicella vaccine was highly effective in preventing mod

126 When administered after exposure, varicella vaccine was highly effective in preventing or

127 mmunization of young children with 1 dose of varicella vaccine was recommended in the United States i

128 Varicella vaccine was safe, immunogenic, and effective i

129 To assess the effectiveness of the varicella vaccine, we conducted a case-control study wit

130 Almost 48 million doses of varicella vaccine were distributed between 1995 and 2005

131 n the offspring of women who were exposed to varicella vaccine while pregnant.

132 rate of zoster in 511 leukemic recipients of varicella vaccine who had 1 or > 1 dose of varicella vac

133 Concomitantly, a version of the varicella vaccine with 10 times the titer was developed